Issn Print: 1085-5629
Publication Date: 2017/03/01
PA-Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER): PA-01:
C Zouboulis; M Okun; R Gniadecki; P Foley; C Lynde; J Weisman; P Karunaratne; D Williams
Author Information: Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany.
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.